COVID-19 Vaccines

Recently, findings of the phase I part of a phase I–II trial of Novavax’s vaccine candidate, which began in May 2020, were released in the New England Journal of Medicine. The vaccine candidate, called NVX-CoV2373, is a recombinant SARS-CoV-2 nanoparticle vaccine created from the full-length, wild-type, virus spike (S) glycoprotein which mediates viral entry in…